The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global bioabsorbable stents market size reached US$ 346.22 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 571.78 Million by 2027, exhibiting a growth rate (CAGR) of 8.40% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Bioabsorbable stents (BRS) are coated with an antiproliferative drug or gene that dissolves over time to restore vessel patency and permit remodeling while retaining recoil. It helps in regulating blood flow at branch points and limiting the amount of blood to areas of the vascular network while maintaining the flow at low perfusion. It also improves lesion imaging with cardiac computed tomography (CT) and magnetic resonance imaging (MRI). In addition, it leaves no residual scaffold, reduces vessel irritation and inflammation, and facilitates repeat treatments to the same site. As a result, BRS finds extensive applications in hospitals and cardiac centers across the globe.
The growing prevalence of cardiovascular diseases due to an unhealthy diet, physical inactivity, and excessive consumption of tobacco and alcohol represents one of the factors driving the market. Moreover, there is a rise in the utilization of percutaneous coronary intervention (PCI) procedures to open a blocked artery for carrying oxygen-rich blood through the body. This, along with the expanding healthcare industry, is contributing to the growth of the market. Besides this, the increasing awareness among the masses about the benefits of bioabsorbable stents is offering lucrative growth opportunities to industry investors. In addition, the growing demand for minimally invasive procedures due to less postoperative pain, fewer operative and postoperative complications, shortened hospital stay, and faster recovery times is positively influencing the market. Apart from this, key market players are extensively investing in research and development (R&D) activities to introduce SLENDER integrated delivery system (IDS) fixed-wire and DIRECT RX bioabsorbable rapid-exchange drug-eluting stent (DES) systems to treat coronary artery disease. They are also focusing on developing polymer-based stents, which is expected to bolster the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global bioabsorbable stents market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on biomaterial, absorption rate, application and end user.
Breakup by Biomaterial:
Breakup by Absorption Rate:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arterius Limited, B. Braun SE, Biotronik SE & Co. KG, Boston Scientific Corporation, Elixir Medical Corporation, Kyoto Medical Planning Co. Ltd., Lepu Medical Technology (Beijing) Co. Ltd., Meril Life Sciences Pvt. Ltd., Reva Medical LLC and Terumo Corporation.
|Base Year of the Analysis||2021|
|Segment Coverage||Biomaterial, Absorption Rate, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Arterius Limited, B. Braun SE, Biotronik SE & Co. KG, Boston Scientific Corporation, Elixir Medical Corporation, Kyoto Medical Planning Co. Ltd., Lepu Medical Technology (Beijing) Co. Ltd., Meril Life Sciences Pvt. Ltd., Reva Medical LLC and Terumo Corporation.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at